MRM Health Appoints Grégoire Franoux as Chief Business Officer and Adds Ron Robison to its Board of Directors

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced the appointment of Grégoire Franoux, M.B.A., to the newly created role of Chief Business Officer. Concurrently, the company has strengthened its Board of Directors with the appointment of industry veteran Ron Robison, M.D.

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy for Inflammatory Bowel Diseases, in two oral presentations during the 2024 Digestive Disease Week® (DDW) meeting, being held May 18-21, 2024 in Washington, D.C. at the Walter E. Washington Convention Center.

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.

MRM Health Initiates Clinical Research in Parkinson’s Disease

MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in Parkinson’s Disease (PD) and to identify PD-specific microbial and metabolic fingerprints in small intestinal fluid and blood. The clinical research is being conducted in close collaboration with Nimble Science and the University of Calgary, Canada.

MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis

MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC).

MRM Health Appoints Katja Conrath as Chief Scientific Officer

MRM Health - a clinical-stage biopharmaceutical company focused on developing innovative microbiome-based biotherapeutics based on its proprietary and unique CORAL® platform technology - today announced that it appointed Katja Conrath, PhD, as Chief Scientific Officer.

MRM Health Completes Patient Recruitment in Ulcerative Colitis Study, Secures Financing and Provides Outlook for 2023

MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics based on its proprietary and unique CORAL® platform technology - today provided a business update on its different ongoing therapeutic programs and an outlook for 2023.

MRM Health and IFF Reach Second Milestone in the partnered Type 2 Diabetes program

MRM Health - a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics - today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved preclinical development targets. With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases to the clinical development stage.

MRM Health Starts Clinical Trial with Next-Generation Optimized Consortium Therapeutic MH002 in Pouchitis

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 2 trial with the novel next-generation optimized consortium therapy, MH002, in patients with Pouchitis.

MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease (NAFLD), with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL® platform technology.

MRM Health to present at the 6th Microbiome Movement Drug Development Europe Summit

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that it will present scientific data from its portfolio at the 6th Microbiome Movement Drug Development Europe Summit, resulting from its proprietary and unique CORAL™ platform technology.

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced that the first patient received MH002 in a phase 1b/2a multi-center clinical trial in mild-to-moderate Ulcerative Colitis. MH002 is MRM Health’s first clinical product candidate resulting from its proprietary and unique CORAL™ platform technology.

MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate ulcerative colitis (UC).

MRM Health presents its proprietary microbiome therapeutics optimization technology at the Microbiome Movement Drug Development Conference

MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, outlined the proprietary technology of the company at the 5th Microbiome Movement - Drug Development Summit Europe 2021.

The presentation, entitled “MRM Health – the Next Level in Optimized Consortia Development”, outlined the company’s innovative and unique approach in developing and manufacturing Optimized Synthetic Consortia as well as its pipeline.

MRM Health appoints Dr. Werner Cautreels as Chairman and Dr. Nigel Horscroft as Chief Scientific Officer

Microbiome specialist MRM Health is pleased to announce the appointment of its Chairman of the Board and its Chief Scientific Officer.

MRM Health NV, a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome, announced today that Dr. Werner Cautreels, former CEO of Solvay Pharmaceuticals and Selecta Biosciences, has been appointed as Chairman of the Board and Dr. Nigel Horscroft, ex-Curevac and Pfizer, as Chief Scientific Officer. In addition, Dr. Ludo Haazen is joining the R&D organization to support clinical development and medical affairs.

MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences and boosts its development with an investment of more than €14 million to redefine microbiome-based therapeutics

Microbiome specialist MRM Health enters into its first industry collaboration with DuPont Nutrition & Biosciences in the field of metabolic diseases. Furthermore, MRM Health has raised more than €14 million to advance its in-house clinical and preclinical development programs in the field of microbiome-based therapeutics and strengthens its partnership with the Flemish Institute of Biotechnology (VIB), KU Leuven and Ghent University.